Oxford Science Enterprises (OSE), an Oxford-based investment firm that uniquely supports startups with its partnership with the University of Oxford, announced on Thursday that its life sciences portfolio company, MiroBio, is set to be acquired by US-based biopharmaceutical company Gilead Sciences for $405M (approximately €396M) in cash.
MiroBio, a spin-off from the University of Oxford, is a clinical-stage private biotechnology company focused on developing therapeutic agents and checkpoint agonist antibodies to restore immune balance in autoimmune patients.